Mianserine Arrow (Mianserin Hydrochloride)

Mianserin blocks presynaptic alpha‑2 adrenergic receptors, which increases norepinephrine release. It also antagonizes histamine H1 and serotonin 5‑HT2/5‑HT3 receptors, resulting in a net rise in serotonergic and noradrenergic activity that contributes to its antidepressant effect.

The dosage of Mianserine Arrow is individualized and determined by the prescribing clinician based on the patient’s clinical response, tolerability, and overall health status. Physicians typically start with a low dose and adjust as needed.

Safety data for Mianserine Arrow during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mianserine Arrow belongs to the tetracyclic class, differing from selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). It has a distinct receptor profile, offering sedative properties and a lower risk of sexual dysfunction compared with many SSRIs, while generally presenting fewer anticholinergic effects than TCAs.

Store Mianserine Arrow at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mianserine Arrow is taken orally. The tablet (or other oral form) should be swallowed whole with a glass of water, preferably with food to reduce gastrointestinal discomfort, unless otherwise directed by the prescriber.

Serious adverse events include agranulocytosis or severe neutropenia, marked hypotension, seizures, cardiac arrhythmias, and severe hepatic dysfunction. Patients should be monitored regularly for signs of blood dyscrasias, cardiovascular changes, and liver injury.

Mianserine Arrow should be avoided in individuals with known hypersensitivity to mianserin or any excipients, those who have taken monoamine oxidase inhibitors within the past 14 days, patients with severe liver impairment, and anyone for whom the risk–benefit profile is unfavorable.